Jacobio Pharma (HKG: 1167) has announced the presentation of preliminary results from the Phase I study of its bromodomain and extra-terminal domain (BET) inhibitor, JAB-8263, in the treatment of myelofibrosis (MF), at the 66th American Society of Hematology (ASH) annual meeting.
JAB-8263 Demonstrates Good Tolerability and Efficacy in Phase I
The study indicated that JAB-8263 has a good tolerability profile, with the recommended Phase II dosage set at 0.3mg daily. This finding is a significant step forward, as tolerability is a key factor in the successful development of new therapeutics. The preliminary efficacy data from the study was also encouraging, showing that most patients experienced splenic atrophy (SVR) and a decrease in total symptom score (TSS), indicating a positive response to the treatment.
Implications of the Results for Myelofibrosis Treatment
The positive preliminary results from the Phase I study of JAB-8263 are an important milestone in the development of potential new treatment options for myelofibrosis patients. The data presented at the ASH annual meeting highlight the potential of JAB-8263 to offer an effective and well-tolerated therapy, which could significantly improve patient outcomes in the future.-Fineline Info & Tech
